Lake Zurich company releases new cancer drug

Fresenius Kabi said Wednesday that it developed a new drug to help prevent nausea and vomiting in cancer chemotherapy patients.

The global health care company in Lake Zurich said the Palonosetron Hydrochloride Injection is now available.

Fresenius Kabi specializes in medicines and technologies for infusion, transfusion and clinical nutrition.

"The addition of Palonosetron to the injectable antiemetic medicines offered by Fresenius Kabi is the latest example of our commitment to offer a large product portfolio to meet the diverse needs of clinicians and patients," said John Ducker, president and CEO of Fresenius Kabi USA.

Palonosetron Hydrochloride Injection is a 5-HT 3 serotonin receptor indicated in adults for moderately emetogenic cancer chemotherapy - prevention of acute and delayed nausea and vomiting associated with initial and repeat courses; highly emetogenic cancer chemotherapy - prevention of acute nausea and vomiting associated with initial and repeat courses; and prevention of postoperative nausea and vomiting for up to 24 hours following surgery. Efficacy beyond 24 hours has not been demonstrated.